Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Tempo Pharmaceuticals Closes $8 Million in Series B Funding

Abstract:
-Company Focused on Developing Nanopharmaceutical Products-

Tempo Pharmaceuticals Closes $8 Million in Series B Funding

Cambridge, MA | Posted on January 3rd, 2008

Tempo Pharmaceuticals, a biopharmaceutical company focused on novel, intelligently designed nanoparticle-based drugs, today announced that it has closed an $8.1 million Series B financing. Proceeds from the financing will be used to accelerate the development of Tempo's preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy and safety of existing and new therapeutics.

Existing venture investors Polaris Venture Partners of Waltham, MA, Venrock of New York, NY, and Lux Capital of New York, NY were joined by Bessemer Venture Partners of Wellesley, MA. Also participating were Alexandria Real Estate Equities and existing investor William H. Rastetter, Ph.D. (former executive chairman of Biogen Idec and a partner at Venrock). Tempo previously closed its $12.1 million Series A round in May, 2007 and its $2 million seed round in December of 2006.

"This new influx of capital at a significantly increased valuation, which brings the total raised within the last year to more than $22 million, reflects the growing excitement and recognition of our unique platform as well as our rapid progress as a company," said Alan Crane, CEO of Tempo Pharmaceuticals and a venture partner at Polaris. "This funding allows the continued advancement of our preclinical pipeline towards human clinical trials and will support the generation of data to enable strategic partnerships with leading biotechnology and pharmaceutical companies."

Based on technology exclusively licensed from the Massachusetts Institute of Technology, Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle. This approach allows for sequential delivery of drugs, optimizing the location, rate of release and synergistic effect of the two therapies while minimizing toxicities.

"Bessemer views nanopharmaceuticals, and in particular, Tempo's approach to nanopharmaceuticals, as an unprecedented investment opportunity within the marketplace," said Christopher Gabrieli, Senior Partner, Bessemer Venture Partners. "We believe this science and technology has the potential to dramatically improve the way diseases are treated, and more specifically, that Tempo has the leading platform and proven management team in place to rapidly develop a portfolio of next generation therapeutics."

Using its proprietary Nanocell technology, Tempo is developing a deep pipeline of preclinical candidates. Its current focus is on application of the technology to both existing and novel drugs for oncology, autoimmune and inflammatory diseases.

About Nanocell Technology

The potential of the Nanocell technology was highlighted by preclinical data published in the July 28, 2005 edition of the journal Nature. In the study, researchers designed a Nanocell that preferentially distributed to a cancerous tumor; the Nanocell then sequentially released a vascular targeting drug, leading to the collapse of the vascular network and trapping the nanoparticle within the tumor, followed by the subsequent release of a potent anti-tumor drug.

The data published in Nature showed that by concentrating and trapping the drugs in the tumor, the Nanocell dramatically inhibited tumor growth in mice and extended survival time compared to other drugs and drug combinations. In addition, the data shows that the Nanocell provides a significant safety advantage in the animal models studied compared with positive controls. Finally, data in the Nature paper demonstrated that the unique format of the Nanocell has the potential to overcome resistance mechanisms of cancer.

About Nanopharmaceuticals and NanoBiology

Nanopharmaceuticals represent a revolutionary new approach to designing drugs and enhancing their properties with the goal of creating improved therapies for fighting disease.

Nanopharmaceuticals are a new type of drug that consist of ultra-small particles containing drugs that are designed to enhance their therapeutic utility. The unique properties of nanopharmaceuticals allow for the delivery of drugs to specific diseased tissues, the controlled release of therapeutic concentrations of drugs over a short or prolonged period of time and improved formulations of established therapies.

Within the field of nanopharmaceuticals, Tempo Pharmaceuticals is uniquely focused an emerging field we call NanoBiology - a next generation approach in which a deep understanding of the complex biological microenvironment of human disease and disease processes combined with engineering therapies on a nanoscale allows the creation of new breakthrough drugs that are intelligently designed to address the root causes of disease.

####

About Tempo Pharmaceuticals
Tempo Pharmaceuticals is a private biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, Pharmacia, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center. Tempo is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Yates Public Relations
Adriana Jenkins
617-744-1713

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New technique for exploring structural dynamics of nanoworld: Developed in a Nobel laureate's laboratory at Caltech, hybrid approach allows ultrafast EM analysis of materials, showing tiny electronic changes in individual atoms within a material on ultrafast time scales April 28th, 2015

When mediated by superconductivity, light pushes matter million times more April 28th, 2015

Chemists strike nano-gold: 4 new atomic structures for gold nanoparticle clusters: Research builds upon work by Nobel Prize-winning team from Stanford University April 28th, 2015

Self-assembling biomaterial forms nanostructure templates for human tissue formation April 27th, 2015

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Harris & Harris Group Portfolio Company OpGen Files Amended Registration Statement for Proposed Public Offering April 8th, 2015

Hong Kong Investors Bullish on Dais Analytic Invest $5.75M, Provide $60M Contract, and Create New Joint Venture Company March 26th, 2015

Nanomedicine

Chemists strike nano-gold: 4 new atomic structures for gold nanoparticle clusters: Research builds upon work by Nobel Prize-winning team from Stanford University April 28th, 2015

Self-assembling biomaterial forms nanostructure templates for human tissue formation April 27th, 2015

International research team discovers new mechanism behind malaria progression: Findings provide a new avenue for research in malaria treatment April 27th, 2015

Scientists join forces to reveal the mass and shape of single molecules April 27th, 2015

Announcements

New technique for exploring structural dynamics of nanoworld: Developed in a Nobel laureate's laboratory at Caltech, hybrid approach allows ultrafast EM analysis of materials, showing tiny electronic changes in individual atoms within a material on ultrafast time scales April 28th, 2015

When mediated by superconductivity, light pushes matter million times more April 28th, 2015

Chemists strike nano-gold: 4 new atomic structures for gold nanoparticle clusters: Research builds upon work by Nobel Prize-winning team from Stanford University April 28th, 2015

Sensor Designed in Iran Able to Remove Formaldehyde Gas from Environment April 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project